Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : TD Cowen
Deal Size : $16.0 million
Deal Type : Public Offering
Atara Biotherapeutics Announces Pricing of $16 Million Offering
Details : The net procceds from the offering will be used to advance the development of Ebvallo (tabelecleucel), which is being evaluated for EBV-positive Post-Transplant Lymphoproliferative Disorders.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : TD Cowen
Deal Size : $16.0 million
Deal Type : Public Offering
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO (tabelecleucel)
Details : Ebvallo (tabelecleucel) is an off-the-shelf allogeneic cell therapy composed of EBV specific cytotoxic T cell lymphocytes, indicated for EBV-associated post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Update on Clinical Programs for EBVALLO™ and ATA3219
Details : FDA has placed a clinical hold on active IND applications of the EBVALLO (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with EBV+ PTLD.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Details : Ebvallo (Tabelecleucel) is a gene therapy which is indicated as a monotherapy for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Priority Review for Tab-cel® in EBV-Positive Lymphoproliferative Disease
Details : Tab-Cel (Tabelecleucel) is a gene therapy which is indicated as a monotherapy for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atara Announces FDA Acceptance and Priority Review of Tabelecleucel for EBV Disease
Details : Tab-Cel (Tabelecleucel) is an allogeneic T-cell immunotherapy targetting EBV-infected cells, which is indicated for the treatment of EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $667.0 million
Deal Type : Partnership
Atara Biotherapeutics Submits Tabelecleucel for EBV Positive Lymphoproliferative Disease
Details : Atara partners with Pierre Fabre for global commercialization of Tab-Cel (Tabelecleucel) for EBV-positive post-transplant lymphoproliferative disease.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : $27.0 million
May 20, 2024
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $667.0 million
Deal Type : Partnership
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : tab-cel (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Atara Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ebvallo™ (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Atara Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $640.0 million
Deal Type : Partnership
Details : Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.
Product Name : Ebvallo
Product Type : Cell and Gene therapy
Upfront Cash : $30.0 million
January 11, 2023
Lead Product(s) : Tabelecleucel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Pierre Fabre
Deal Size : $640.0 million
Deal Type : Partnership